The role of aspirin in cancer prevention, Nat. Rev. Clin. Oncol, vol.9, pp.259-267, 2012. ,
, C. Aspirin and Cancer. J. Am. Coll. Cardiol, vol.68, pp.967-976, 2016.
Aspirin, platelet inhibition and cancer prevention, Platelets, vol.29, pp.779-785, 2018. ,
Antiplatelet agents for cancer treatment: A real perspective or just an echo from the past?, Cancer Metastasis Rev, vol.36, pp.305-329, 2017. ,
Cancer and platelet crosstalk: Opportunities and challenges for aspirin and other antiplatelet agents, Blood, vol.131, pp.1777-1789, 2018. ,
Aspirin and colorectal cancer: The promise of precision chemoprevention, Nat. Rev. Cancer, vol.16, pp.173-186, 2016. ,
Antithrombotic Agents and Cancer, Cancers, vol.10, 2018. ,
Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann. Intern. Med, vol.164, pp.836-845, 2016. ,
Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer, Gastroenterology, vol.147, pp.502-526, 2014. ,
, NICE Guideline on Colorectal Cancer: Diagnosis and Management, p.24, 2019.
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus, N. Engl. J. Med, vol.379, pp.1529-1539, 2018. ,
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial, Lancet, vol.392, pp.1036-1046, 2018. ,
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly, N. Engl. J. Med, vol.379, pp.1519-1528, 2018. ,
Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study, Cancer Res, vol.48, pp.4399-4404, 1988. ,
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence, J. Natl. Cancer Inst, vol.99, pp.608-615, 2007. ,
Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study, Ann. Intern. Med, vol.163, pp.347-355, 2015. ,
Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer, JAMA Oncol, vol.2, pp.762-769, 2016. ,
Aspirin for Cancer Prevention: One Step Closer, JAMA Oncol, vol.2, pp.770-771, 2016. ,
Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study, Ann. Intern. Med, vol.128, pp.713-720, 1998. ,
Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial, JAMA, vol.294, pp.47-55, 2005. ,
Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial, Ann. Intern. Med, vol.159, pp.77-85, 2013. ,
Randomised trial of prophylactic daily aspirin in British male doctors, Br. Med. J. (Clin. Res. Ed.), vol.296, pp.313-316, 1988. ,
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results, J. Neurol. Neurosurg. Psychiatry, vol.54, pp.1044-1054, 1991. ,
British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies, Lancet, vol.369, pp.1603-1613, 2007. ,
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, vol.376, pp.1741-1750, 2010. ,
Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force, Ann. Intern. Med, vol.164, pp.814-825, 2016. ,
Estimates of benefits and harms of prophylactic use of aspirin in the general population, Ann. Oncol, vol.26, pp.47-57, 2015. ,
Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials, Lancet Oncol, vol.13, pp.518-527, 2012. ,
Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants, JAMA, vol.313, pp.1133-1142, 2015. ,
Aspirin use and reduced risk of fatal colon cancer, N. Engl. J. Med, vol.325, pp.1593-1596, 1991. ,
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force, Ann. Intern. Med, vol.164, pp.826-835, 2016. ,
Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force, Ann. Intern. Med, vol.164, pp.777-786, 2016. ,
A randomized trial of aspirin to prevent colorectal adenomas, N. Engl. J. Med, vol.348, pp.891-899, 2003. ,
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer, N. Engl. J. Med, vol.348, pp.883-890, 2003. ,
Aspirin and folic acid for the prevention of recurrent colorectal adenomas, Gastroenterology, vol.134, pp.29-38, 2008. ,
Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial, Gastroenterology, vol.125, pp.328-336, 2003. ,
Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials, J. Natl. Cancer Inst, vol.101, pp.256-266, 2009. ,
The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: A randomised trial, Gut, vol.63, pp.1755-1759, 2014. ,
Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial, Gastroenterology, vol.150, pp.114-122, 2016. ,
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): A multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial, Lancet, vol.392, pp.2583-2594, 2018. ,
, Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk, Lancet, vol.351, pp.233-241, 1998.
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events, Lancet, vol.338, pp.1345-1349, 1991. ,
Milestones of Lynch syndrome, Nat. Rev. Cancer, vol.15, pp.181-194, 2015. ,
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome, N. Engl. J. Med, vol.359, pp.2567-2578, 2008. ,
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial, Lancet, vol.378, pp.2081-2087, 2011. ,
Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome, J. Natl. Cancer Inst, vol.107, 2015. ,
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epidemiol. Biomark. Prev, vol.7, pp.97-102, 1998. ,
Risk factors for squamous cell carcinoma of the oesophagus in women: A case-control study, Br. J. Cancer, vol.85, pp.1667-1670, 2001. ,
Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: Results from a cohort study and a meta-analysis, Br. J. Cancer, vol.100, pp.551-557, 2009. ,
Aspirin and reduced risk of esophageal carcinoma, Cancer, vol.76, pp.1116-1119, 1995. ,
Aspirin protects against gastric cancer: Results of a case-control study from, Int. J. Cancer, vol.82, pp.473-476, 1999. ,
Aspirin use and lung, colon, and breast cancer incidence in a prospective study, Epidemiology, vol.5, pp.138-146, 1994. ,
Aspirin and lung cancer risk in a cohort study of women: Dosage, duration and latency, Br. J. Cancer, vol.97, pp.1295-1299, 2007. ,
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: Results of a case control study, Int. J. Biol. Sci, vol.3, pp.328-334, 2007. ,
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention with Risk of Lung Cancer, JAMA Netw. Open, vol.2, 2019. ,
Aspirin use and breast cancer risk: A meta-analysis, Breast Cancer Res. Treat, vol.131, pp.581-587, 2012. ,
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study, Breast Cancer Res, vol.21, 2019. ,
Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants, Oncotarget, vol.8, pp.40389-40401, 2017. ,
Aspirin use and risk of breast cancer: Systematic review and meta-analysis of observational studies, Cancer Epidemiol. Biomark. Prev, vol.24, pp.1645-1655, 2015. ,
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials, Lancet, vol.379, pp.1602-1612, 2012. ,
Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis, JAMA, vol.321, pp.277-287, 2019. ,
Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials, Lancet, vol.377, pp.31-41, 2011. ,
Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials, Arch. Intern. Med, vol.172, pp.209-216, 2012. ,
Low-dose aspirin and cancer mortality: A meta-analysis of randomized trials, Am. J. Med, vol.125, pp.560-567, 2012. ,
Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials, Lancet, vol.379, pp.1591-1601, 2012. ,
Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?, PLoS ONE, vol.13, 2018. ,
Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer, J. Med, vol.13, pp.419-429, 1982. ,
The "Petites Cellules" Group. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy, vol.71, pp.1741-1745, 1993. ,
A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma, J. Clin. Oncol, vol.9, pp.2104-2109, 1991. ,
ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer, J. Clin. Oncol, vol.36, 2018. ,
ASCOLT Trial Investigators. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer-The ASCOLT study: Study protocol for a randomized controlled trial, Trials, vol.12, 2011. ,
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours, Contemp. Clin. Trials, vol.51, pp.56-64, 2016. ,
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): A study protocol for a randomized controlled trial, Trials, vol.18, 2017. ,
P2Y12 Receptors in Tumorigenesis and Metastasis, Front. Pharmacol, vol.9, p.66, 2018. ,
Anti-platelet treatments in cancer: Basic and clinical research, Thromb. Res, vol.164, pp.106-111, 2018. ,
The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice, PLOS ONE, vol.11, 2016. ,
The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence, Am. J. Med, vol.130, pp.826-832, 2017. ,
Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer, Clin. Gastroenterol. Hepatol, vol.17, pp.2024-2033, 2018. ,
Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor, Thromb. Res, vol.174, pp.51-58, 2019. ,
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges, Thromb. Haemost, vol.114, pp.1104-1112, 2015. ,
The Dual Antiplatelet Therapy Trial after the FDA Update: Noncardiovascular Deaths, Cancer and Optimal Treatment Duration, Cardiology, vol.132, pp.74-80, 2015. ,
CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, vol.348, pp.1329-1339, 1996. ,
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N. Engl. J. Med, vol.354, pp.1706-1717, 2006. ,
Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N. Engl. J. Med, vol.345, pp.494-502, 2001. ,
Clopidogrel for the Reduction of Events during Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial, JAMA, vol.288, pp.2411-2420, 2002. ,
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, N. Engl. J. Med, vol.357, 2001. ,
Weighing Benefits and Risks-The FDA's Review of Prasugrel, N. Engl. J. Med, vol.361, pp.942-945, 2009. ,
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents, N. Engl. J. Med, vol.371, pp.2155-2166, 2014. ,
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization, N. Engl. J. Med, vol.367, pp.1297-1309, 2012. ,
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome, Eur. Heart J, vol.37, pp.412-422, 2016. ,
Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis, Drug Saf, vol.40, pp.229-240, 2017. ,
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis, Circ. Cardiovasc. Interv, vol.11, 2018. ,
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes, N. Engl. J. Med, vol.366, pp.20-33, 2012. ,
Vorapaxar in the secondary prevention of atherothrombotic events, N. Engl. J. Med, vol.366, pp.1404-1413, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00932160
Clopidogrel use and cancer-specific mortality: A population-based cohort study of colorectal, breast and prostate cancer patients, Pharmacoepidemiol. Drug Saf, vol.24, pp.830-840, 2015. ,
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2019 by the authors. Licensee MDPI